Get the Stockscreener App
3.65
0.55%
0.02
Envveno Medical Corporation stock is traded at $3.65, with a volume of 30,063.
It is up +0.55% in the last 24 hours and up +58.70% over the past month.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$3.63
Open:
$3.65
24h Volume:
30,063
Relative Volume:
0.33
Market Cap:
$62.25M
Revenue:
-
Net Income/Loss:
$-24.05M
P/E Ratio:
-1.6977
EPS:
-2.15
Net Cash Flow:
$-17.78M
1W Performance:
+2.82%
1M Performance:
+58.70%
6M Performance:
+3.99%
1Y Performance:
-26.56%
1-Day Range:
$3.5607
$3.68
1-Week Range:
$3.45
$3.97
52-Week Range:
$2.0278
$6.48
Envveno Medical Corporation Stock (NVNO) Company Profile
Name
Envveno Medical Corporation
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.65 | 62.25M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Envveno Medical Corporation Stock (NVNO) Latest News
Geode Capital Management LLC Increases Stake in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO: Financial Position Supports Key Developments Ahead | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Eyes Commercial Transition with VenoValve - GuruFocus
enVVeno Medical Reports First Quarter 2025 Financial Results and - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Eagle-Tribune
enVVeno Medical Reports Strong Q1 Financials with $38.9M War Chest for VenoValve FDA Launch - Stock Titan
JPMorgan Chase & Co. Buys New Shares in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium | NVNO Stock News - GuruFocus
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Weatherford Democrat
enVVeno Medical Corp appoints CBIZ CPAs as new auditor By Investing.com - Investing.com South Africa
enVVeno Medical Corp appoints CBIZ CPAs as new auditor - Investing.com Australia
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment | NVNO Stock News - GuruFocus
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Weatherford Democrat
Live Today: enVVeno Medical Unveils Game-Changing Venous Valve Technology - Stock Titan
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer - ACCESS Newswire
Financial Analysis: ClearPoint Neuro (NASDAQ:CLPT) vs. enVVeno Medical (NASDAQ:NVNO) - Defense World
NVNO stock touches 52-week low at $2.45 amid market challenges - Investing.com
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely - simplywall.st
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Weatherford Democrat
Virtu Financial LLC Buys Shares of 28,533 enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
VenoValve trial shows sustained patient benefits at 24 months - MSN
Sanctuary Advisors LLC Makes New Investment in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - BioSpace
enVVeno Medical (NVNO) to Release Earnings on Thursday - MarketBeat
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical Files For Mixed Shelf Of Up To $100 MillionSEC Filing - TradingView
enVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last year - TipRanks
NVNOEnvveno Medical Corporation Latest Stock News & Market Updates - StockTitan
EnVVeno Medical Reports Fourth Quarter and Year-End 2024 Financi - News Channel Nebraska
Can enVVeno's $43M Cash Runway Carry VenoValve Through FDA Approval? Clinical Data Shows 78% Success Rate - Stock Titan
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing - ACCESS Newswire
enVVeno Medical (NVNO) Projected to Post Quarterly Earnings on Thursday - Defense World
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
enVVeno Medical (NASDAQ:NVNO) Shares Up 6.4%Here's Why - MarketBeat
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference - ACCESS Newswire
One-year data from VenoValve US pivotal trial highlighting impact on patients’ QoL presented at AVF 2025 - Venous News
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - BioSpace
enVVeno Announces One Year Data from VenoValve U.S. Pivotal Trial - MPO-mag
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Can These 5 Growth Drivers Make enVVeno Medical the Next Big Thing in Venous Disease Treatment? - StockTitan
enVVeno Medical presents one-year data from VenoValve trial - TipRanks
Envveno Medical Corporation Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):